Leerink Partners Issues Positive Forecast for Elevance Health (NYSE:ELV) Stock Price

Elevance Health (NYSE:ELV) had its price target hoisted by Leerink Partners from $350.00 to $357.00 in a research note published on Thursday,MarketScreener reports. They currently have a market perform rating on the stock.

Other equities research analysts have also recently issued reports about the company. Barclays set a $393.00 target price on Elevance Health in a report on Friday. Truist Financial set a $400.00 price target on shares of Elevance Health in a report on Tuesday, October 14th. Robert W. Baird increased their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. UBS Group set a $400.00 price objective on shares of Elevance Health in a report on Thursday. Finally, Bank of America upped their target price on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Twelve equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $398.16.

Elevance Health Trading Down 0.5%

Shares of NYSE:ELV traded down $1.73 on Thursday, hitting $345.25. 242,181 shares of the company’s stock were exchanged, compared to its average volume of 1,687,296. The business’s 50 day simple moving average is $351.21 and its two-hundred day simple moving average is $328.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The stock has a market capitalization of $76.73 billion, a price-to-earnings ratio of 13.72, a price-to-earnings-growth ratio of 1.86 and a beta of 0.51. Elevance Health has a 12 month low of $273.71 and a 12 month high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts anticipate that Elevance Health will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.39%.

Hedge Funds Weigh In On Elevance Health

Several hedge funds have recently modified their holdings of the stock. Evergreen Wealth Management LLC boosted its position in Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after purchasing an additional 4,336 shares in the last quarter. Canoe Financial LP increased its stake in Elevance Health by 18.1% during the 3rd quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock worth $125,823,000 after buying an additional 59,743 shares in the last quarter. Synergy Asset Management LLC boosted its stake in shares of Elevance Health by 100.0% in the third quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock worth $33,712,000 after acquiring an additional 52,167 shares during the last quarter. Delta Investment Management LLC purchased a new stake in shares of Elevance Health during the third quarter worth approximately $7,629,000. Finally, OLD National Bancorp IN grew its holdings in shares of Elevance Health by 44.8% during the second quarter. OLD National Bancorp IN now owns 6,267 shares of the company’s stock worth $2,438,000 after buying an additional 1,939 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat and strong Carelon performance: ELV reported quarterly EPS above consensus and rising premiums with Carelon revenue growth, driving the immediate bullish reaction. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Analyst sentiment and dividend hike support investor confidence: Brokerages maintain a generally constructive view (“Moderate Buy”) and the company raised its quarterly dividend slightly, supporting income-oriented investors.
• Neutral Sentiment: Short-term technical/mean-reversion signal noted: Some analysts point to a historically bullish signal after the recent extreme moves, suggesting potential for a bounce but also highlighting continued volatility. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: 2026 profit guidance below Street expectations and flagged revenue decline: Management’s FY‑2026 guidance and commentary signaled lower profit and a revenue headwind next year, which caps upside from the beat and is a key reason investors trimmed positions. Elevance forecasts 2026 profit below estimates, flags revenue decline
• Negative Sentiment: Medicare Advantage rate proposal and membership/margin pressures are headwinds: CMS’s proposed ~0.09% MA rate increase for 2027 and ongoing membership shifts and higher medical expenses are pressuring margins and the 2026 outlook. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts Shape 2026 Outlook

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.